Last news
Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

Innovent and HUTCHMED Jointly Announce NMPA Conditional Approval for TYVYT® (Sintilimab Injection) in Combination with ELUNATE® (Fruquintinib) for the Treatment of Advanced Endometrial Cancer

SAN FRANCISCO, U.S. and SUZHOU, China, Dec. 4, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment...

CNEY Receives NASDAQ Minimum Bid Price Requirement Extension

CNEY Receives NASDAQ Minimum Bid Price Requirement Extension

LISHUI, China, Dec. 4, 2024 /PRNewswire/ -- CN Energy Group. Inc. (NASDAQ: CNEY) ("CNEY" or the "Company") today announced that on November 26, 2024, the Company received a written notice from the Listing Qualifications Staff of The Nasdaq Stock...

Appian Unveils Latest Platform Release for Better Process and Better Outcomes

Appian Unveils Latest Platform Release for Better Process and Better Outcomes

New enhancements scale high-volume workflows and increase efficiency and analysis with AI MCLEAN, Va., Dec. 3, 2024 /PRNewswire/ -- Appian (Nasdaq: APPN) today announced its latest platform release, which delivers process automation powered by...

Half of Australians live with chronic health conditions, over a third forced to leave their jobs as a result

Half of Australians live with chronic health conditions, over a third forced to leave their jobs as a result

Patient advocates call for more support for Australian workers living with a chronic condition/s following the release of a new insights report SYDNEY, Dec. 4, 2024 /PRNewswire/ -- A new report released today has found that of the one in two...

Asia's Transformative Era: Unveiling the "Asian Dream" through New Study "Truth About Ascending Asia"

Asia's Transformative Era: Unveiling the "Asian Dream" through New Study "Truth About Ascending Asia"

SINGAPORE, Dec. 4, 2024 /PRNewswire/ -- McCann Worldgroup has launched its latest insights study, the Truth about Ascending Asia, at an event held at Singapore's Asian Civilisations Museum. Over 70 clients, partners and media joined the advertising...

China Clean Expo 2025, Taking Your Cleaning Business to a New Height!

China Clean Expo 2025, Taking Your Cleaning Business to a New Height!

SHANGHAI, Dec. 4, 2024 /PRNewswire/ -- 26th China Clean Expo (CCE), organized by IM Sinoexpo and supported by ISSA – The worldwide cleaning industry association, will take place at Shanghai New International Expo Center (SNIEC) from March 31st to...

Hublot celebrates the 25th Anniversary of OpusX with a special edition Classic Fusion Chronograph

Hublot celebrates the 25th Anniversary of OpusX with a special edition Classic Fusion Chronograph

CLASSIC FUSION CHRONOGRAPH ARTURO FUENTE KING GOLD To stay up-to-date, follow: @Hublot #Hublot SANTIAGO DE LOS CABALLEROS, Dominican Republic, Dec. 4, 2024 /PRNewswire/ -- A shared drive towards uncompromising excellence and a passion for enjoying...

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery

VivaVision Announces Positive Topline Results from Phase 2 Trial of VVN461 for Post-Operative Inflammation Following Cataract Surgery

VVN461, a non-steroidal dual JAK1/TYK2 immunomodulator, achieves primary endpoint, demonstrating statistical and clinical efficacy compared to vehicle in treating post-operative inflammation following cataract surgery Statistically and clinically...

menu
menu